FDA Approves Datopotamab Deruxtecan-dlnk for Unresectable or Metastatic TNBC By Ogkologos - June 24, 2026 152 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the TROPION-Breast02 study Source RELATED ARTICLESMORE FROM AUTHOR Comprehensive Genomic Profiling with Subsequent Molecularly Guided Therapy Improves Outcomes Over Platinum-based Chemotherapy in Previously Untreated, Unfavourable CUP NCI and CRUK Take on Cancer’s Toughest Problems Tebentafusp Continues to Provide Long-Term OS Benefit in Previously Untreated Patients with Unresectable or Metastatic Uveal Melanoma MOST POPULAR Researchers Discover Genetic Marker That Increases Risk Of Premenopausal Breast Cancer August 2, 2019 ESMO Joins the European Health Alliance on Alcohol (EHAA) Seeking to... August 14, 2025 Lockdown Keeping Young Mother with Metastatic Breast Cancer from Saying Goodbye... April 22, 2021 Many Men with Metastatic Prostate Cancer Are Not Getting the Recommended... February 18, 2025 Load more HOT NEWS Opportunity and mentorship: Our new PhD programme aiming to open-up academia... 2021 ASCO Annual Meeting Research Round Up: Advances in Genitourinary Cancers Intratumoural and Intracavitary Administration of Ipilimumab Plus Nivolumab Is Feasible and... Recognising the essential role of clinical research nurses
